Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Sørensen AL, Mikkelsen SU, Knudsen TA, Bjørn ME, Andersen CL, Bjerrum OW, Brochmann N, Patel DA, Gjerdrum LMR, El Fassi D, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Ellervik C, Pallisgaard N, Thomassen M, Kjær L, Skov V, Hasselbalch HC.

Haematologica. 2019 Dec 26. pii: haematol.2019.235648. doi: 10.3324/haematol.2019.235648. [Epub ahead of print]

2.

Remembering visceral leishmaniasis as a potential trigger of haemophagocytic lymphohistiocytosis in individuals treated with anti-TNF-alpha therapy.

Nardo-Marino A, Bukan K, Nielsen HV, El Fassi D.

Eur J Rheumatol. 2019 Aug 20;6(4):226-227. doi: 10.5152/eurjrheum.2019.18178. Print 2019 Oct. No abstract available.

3.

Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy.

Bukan KB, Nardo-Marino A, Hagdrup C, Boennelycke M, Breinholdt MF, Schöllkopf C, Nielsen HV, El Fassi D.

Scand J Rheumatol. 2019 Jul;48(4):342-343. doi: 10.1080/03009742.2018.1533035. Epub 2018 Dec 10. No abstract available.

PMID:
30526204
4.

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.

El Fassi D.

N Engl J Med. 2015 Dec 24;373(26):2579. doi: 10.1056/NEJMc1512663. No abstract available.

PMID:
26699177
5.

Hyperkalemia: a clue to the diagnosis of adrenal insufficiency.

El Fassi D, Nielsen G.

Circulation. 2013 Dec 17;128(24):2620-1. doi: 10.1161/CIRCULATIONAHA.113.005169. No abstract available.

PMID:
24344062
6.

Anti-CD20 antibody therapy for B-cell lymphomas.

El Fassi D, Hegedüs L, Nielsen CH.

N Engl J Med. 2012 Aug 30;367(9):877; author reply 878. doi: 10.1056/NEJMc1207378. No abstract available.

PMID:
22931339
7.

[Treatment of metformin-associated lactate acidosis by haemodialysis].

Schousboe K, El Fassi D, Secher EL, Elming H, Rasmussen K, Hornum M.

Ugeskr Laeger. 2012 Jun 4;174(23):1604-6. Danish.

PMID:
22673381
8.

Ulcerative colitis.

El Fassi D, Nielsen CH.

N Engl J Med. 2012 Mar 1;366(9):862; author reply 862-3. doi: 10.1056/NEJMc1113995. No abstract available.

PMID:
22375991
9.

Systemic adverse events following rituximab therapy in patients with Graves' disease.

El Fassi D, Nielsen CH, Junker P, Hasselbalch HC, Hegedüs L.

J Endocrinol Invest. 2011 Jul-Aug;34(7):e163-7. doi: 10.3275/7411. Epub 2010 Dec 15.

PMID:
21169731
10.

[Laughter-induced pressure pneumothorax].

Andreasen DB, Kirkeby LT, El Fassi D.

Ugeskr Laeger. 2010 Dec 13;172(50):3499. Danish. No abstract available.

PMID:
21156117
11.

[The Pilgaard-Dahl syndrome: laughter-induced pneumothorax].

Andreasen DB, El Fassi D.

Ugeskr Laeger. 2010 Dec 13;172(50):3496-8. Danish.

PMID:
21156116
12.

Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.

Nielsen JF, El Fassi D, Nielsen CH, Hegedüs L, Lauer SA, Silkiss RZ, Prause JU.

Acta Ophthalmol. 2009 Nov;87(8):927-9. doi: 10.1111/j.1755-3768.2009.01647.x. No abstract available.

13.

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.

El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH.

Clin Immunol. 2009 Mar;130(3):252-8. doi: 10.1016/j.clim.2008.09.007. Epub 2008 Oct 28.

PMID:
18964302
14.

Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.

Banga JP, Nielsen CH, Gilbert JA, El Fassi D, Hegedus L.

Thyroid. 2008 Sep;18(9):973-81. doi: 10.1089/thy.2007.0406. Review.

PMID:
18752425
15.

[Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].

Nielsen CH, El Fassi D, Hegedüs L.

Ugeskr Laeger. 2008 Jun 9;170(24):2131-4. Danish.

PMID:
18565295
16.

[Biological treatment options for Graves' ophthalmopathy].

El Fassi D, Nielsen CH, Hegedüs L.

Ugeskr Laeger. 2008 Jun 9;170(24):2128-30. Danish.

PMID:
18565294
17.

Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease.

El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedüs L.

Gut. 2008 May;57(5):714-5. doi: 10.1136/gut.2007.138305. No abstract available.

PMID:
18408106
18.

Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease.

El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L.

J Clin Endocrinol Metab. 2007 Oct;92(10):3762-3. No abstract available.

PMID:
17933978
19.

B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.

Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L.

Expert Opin Biol Ther. 2007 Jul;7(7):1061-78. Review.

PMID:
17665994
20.

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.

El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L.

J Clin Endocrinol Metab. 2007 May;92(5):1769-72. Epub 2007 Feb 6.

PMID:
17284622
21.

[Rituximab (MabThera) as treatment of active rheumatoid arthritis].

El Fassi D, Nielsen CH, Bendtzen K.

Ugeskr Laeger. 2006 Nov 20;168(47):4079-81. Danish.

PMID:
17134602
22.

Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion.

El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L.

Thyroid. 2006 Jul;16(7):709-10. No abstract available.

PMID:
16889501
23.

The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.

El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L.

Eur J Endocrinol. 2006 May;154(5):623-32. Review.

PMID:
16645007

Supplemental Content

Loading ...
Support Center